Cargando…
A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults
Background: This study was conducted to explore the safety, tolerance, pharmacokinetics, pharmacodynamics, and immunogenicity of LY06006, a recombinant humanized monoclonal antibody to RANKL, when administrated subcutaneously in Chinese healthy adults. Research design and methods: This was a randomi...
Autores principales: | Niu, Suping, Chen, Min, Yan, Diqin, Liu, Xiangxing, Guo, Shuren, Ou, Lun, Fan, Huaying, Lv, Jie, Wang, Qian, Dong, Wenliang, Xia, Lin, Wang, Simin, Liu, Gang, Gu, Qun, Guo, Danjie, Liu, Hongxia, Rao, Huiying, Zheng, Qingshan, Nie, Xiaoyan, Song, Haifeng, Fang, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240259/ https://www.ncbi.nlm.nih.gov/pubmed/35784742 http://dx.doi.org/10.3389/fphar.2022.893166 |
Ejemplares similares
-
Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
por: Gu, Jiemei, et al.
Publicado: (2022) -
The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies
por: Yan, Diqin, et al.
Publicado: (2022) -
Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
por: Hu, Dingyuan, et al.
Publicado: (2023) -
A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
por: Ding, Yanhua, et al.
Publicado: (2023) -
Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)